Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TransEnterix Inc.
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer
The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.
The global market for endoscopic and pelvic surgery procedures is expected to reach $17.7bn in 2023, a CAGR of 6.4%, driven by patients' demand for less invasive surgeries and physicians' preference for minimally invasive surgeries versus open surgeries. By 2023, the number of general and pelvic endoscopic procedures performed globally will reach about 29.7 million, representing a CAGR of 3.6%.
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- MST Medical Surgery Technologies Ltd
- SafeStitch Medical
- TransEnterix Israel, Ltd.